Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


OLIENA
Language recovery after stroke
App | Video | PDF (278 pp) | Web

  Breast Cancer

  Free Subscription


Articles published in Int J Cancer

Retrieve available abstracts of 118 articles:
HTML format
Text format



Single Articles


    May 2018
  1. WU W, Chen F, Cui X, Yang L, et al
    LncRNA NKILA Suppresses TGF-beta-induced Epithelial-Mesenchymal Transition by Blocking NF-kappaB Signaling in Breast Cancer.
    Int J Cancer. 2018 May 15. doi: 10.1002/ijc.31605.
    PubMed     Text format     Abstract available


  2. LI J, Jing R, Wei H, Wang M, et al
    Germline mutations in 40 cancer susceptibility genes among Chinese patients with high hereditary risk breast cancer.
    Int J Cancer. 2018 May 12. doi: 10.1002/ijc.31601.
    PubMed     Text format     Abstract available


  3. TROISI R, Gulbech Ording A, Grotmol T, Glimelius I, et al
    Pregnancy Complications and Subsequent Breast Cancer Risk in the Mother: A Nordic population-based case-control study.
    Int J Cancer. 2018 May 11. doi: 10.1002/ijc.31600.
    PubMed     Text format     Abstract available


  4. LA MANNA S, Lee E, Ouzounova M, Di Natale C, et al
    Mimetics of Suppressor of cytokine signalling 3: novel potential therapeutics in triple breast cancer.
    Int J Cancer. 2018 May 11. doi: 10.1002/ijc.31594.
    PubMed     Text format     Abstract available


  5. OH E, Kim YJ, An H, Sung D, et al
    Flubendazole elicits anti-metastatic effects in triple-negative breast cancer via STAT3 inhibition.
    Int J Cancer. 2018 May 9. doi: 10.1002/ijc.31585.
    PubMed     Text format     Abstract available


  6. FAN C, Zhang J, Ouyang T, Li J, et al
    RAD50 germline mutations are associated with poor survival in BRCA1/2-negative breast cancer patients.
    Int J Cancer. 2018 May 4. doi: 10.1002/ijc.31579.
    PubMed     Text format     Abstract available


    April 2018
  7. BAGLIA ML, Cook LS, Tang MT, Wiggins C, et al
    Alcohol, Smoking, and Risk of Her2-Overexpressing and Triple-Negative Breast Cancer Relative to Estrogen Receptor-Positive Breast Cancer.
    Int J Cancer. 2018 Apr 30. doi: 10.1002/ijc.31575.
    PubMed     Text format     Abstract available


  8. CAIRAT M, Fournier A, Murphy N, Biessy C, et al
    Nonsteroidal anti-inflammatory drug use and breast cancer risk in a European prospective cohort study.
    Int J Cancer. 2018 Apr 29. doi: 10.1002/ijc.31570.
    PubMed     Text format     Abstract available


  9. LI J, Wang W, Xia P, Wan L, et al
    Identification of a five-lncRNA signature for predicting the risk of tumor recurrence in breast cancer patients.
    Int J Cancer. 2018 Apr 29. doi: 10.1002/ijc.31573.
    PubMed     Text format     Abstract available


  10. AL-AWADHI A, Murray JL, Ibrahim NK
    Developing Anti-HER2 Vaccines: Breast Cancer Experience.
    Int J Cancer. 2018 Apr 25. doi: 10.1002/ijc.31551.
    PubMed     Text format     Abstract available


  11. WILKE CM, Braselmann H, Hess J, Klymenko SV, et al
    A genomic copy number signature predicts radiation exposure in post-Chernobyl breast cancer.
    Int J Cancer. 2018 Apr 16. doi: 10.1002/ijc.31533.
    PubMed     Text format     Abstract available


  12. BOCK J, Appenzeller S, Haertle L, Schneider T, et al
    Single CpG hypermethylation, allele methylation errors, and decreased expression of multiple tumor suppressor genes in normal body cells of mutation-negative early-onset and high-risk breast cancer patients.
    Int J Cancer. 2018 Apr 16. doi: 10.1002/ijc.31526.
    PubMed     Text format     Abstract available


  13. SHAFIEE A, McGovern JA, Lahr CA, Meinert C, et al
    Immune System Augmentation via Humanization Using Stem/Progenitor Cells and Bioengineering in a Breast Cancer Model Study.
    Int J Cancer. 2018 Apr 16. doi: 10.1002/ijc.31528.
    PubMed     Text format     Abstract available


  14. CAO C, Wu H, Vasilatos SN, Chandran U, et al
    HDAC5-LSD1 Axis Regulates Antineoplastic Effect of Natural HDAC Inhibitor Sulforaphane in Human Breast Cancer Cells.
    Int J Cancer. 2018 Apr 6. doi: 10.1002/ijc.31419.
    PubMed     Text format     Abstract available


  15. NJOR SH, Paci E, Rebolj M
    As you like it: How the same data can support manifold views of overdiagnosis in breast cancer screening.
    Int J Cancer. 2018 Apr 6. doi: 10.1002/ijc.31420.
    PubMed     Text format     Abstract available


    March 2018
  16. ERIKSSON L, Bergh J, Humphreys K, Warnberg F, et al
    Time from breast cancer diagnosis to therapeutic surgery and breast cancer prognosis: A population-based cohort study.
    Int J Cancer. 2018 Mar 31. doi: 10.1002/ijc.31411.
    PubMed     Text format     Abstract available


  17. YUE W, Wang J, Atkins KA, Bottalico L, et al
    Effect of a tissue selective estrogen complex (TSEC) on breast cancer: Role of unique properties of conjugated equine estrogen.
    Int J Cancer. 2018 Mar 25. doi: 10.1002/ijc.31401.
    PubMed     Text format     Abstract available


  18. DE MUNCK L, Fracheboud J, de Bock GH, den Heeten GJ, et al
    Is the incidence of advanced-stage breast cancer affected by whether women attend a steady-state screening program?
    Int J Cancer. 2018 Mar 25. doi: 10.1002/ijc.31388.
    PubMed     Text format     Abstract available


  19. GUINTER MA, McLain AC, Merchant AT, Sandler DP, et al
    A dietary pattern based on estrogen metabolism is associated with breast cancer risk in a prospective cohort of postmenopausal women.
    Int J Cancer. 2018 Mar 25. doi: 10.1002/ijc.31387.
    PubMed     Text format     Abstract available


  20. GUO W, Key TJ, Reeves GK
    Adiposity and breast cancer risk in postmenopausal women: Results from the UK Biobank prospective cohort.
    Int J Cancer. 2018 Mar 23. doi: 10.1002/ijc.31394.
    PubMed     Text format     Abstract available


  21. WRIGHT LB, Schoemaker MJ, Jones ME, Ashworth A, et al
    Breast cancer risk in relation to history of preeclampsia and hyperemesis gravidarum: Prospective analysis in the Generations Study.
    Int J Cancer. 2018 Mar 8. doi: 10.1002/ijc.31364.
    PubMed     Text format     Abstract available


  22. ABUBAKAR M, Chang-Claude J, Ali HR, Chatterjee N, et al
    Etiology of hormone receptor positive breast cancer differs by levels of histologic grade and proliferation.
    Int J Cancer. 2018 Mar 1. doi: 10.1002/ijc.31352.
    PubMed     Text format     Abstract available


    February 2018
  23. GATHIRUA-MWANGI WG, Song Y, Monahan P, Champion VL, et al
    Associations of Metabolic syndrome and C-reactive protein with Mortality from total cancer, obesity-linked cancers and Breast Cancer among Women in NHANES III.
    Int J Cancer. 2018 Feb 27. doi: 10.1002/ijc.31344.
    PubMed     Text format     Abstract available


  24. LAN B, Ma F, Zhai X, Li Q, et al
    The relationship between the CYP2D6 polymorphisms and tamoxifen efficacy in adjuvant endocrine therapy of breast cancer patients in Chinese Han population.
    Int J Cancer. 2018 Feb 3. doi: 10.1002/ijc.31291.
    PubMed     Text format     Abstract available


    January 2018
  25. RIAHI A, Radmanesh H, Schurmann P, Bogdanova N, et al
    Exome sequencing and case-control analyses identify RCC1 as a candidate breast cancer susceptibility gene.
    Int J Cancer. 2018 Jan 24. doi: 10.1002/ijc.31273.
    PubMed     Text format     Abstract available


  26. BUSUND M, Bugge NS, Braaten T, Waaseth M, et al
    Progestin-Only and Combined Oral Contraceptives and Receptor-Defined Premenopausal Breast Cancer Risk: The Norwegian Women and Cancer Study.
    Int J Cancer. 2018 Jan 19. doi: 10.1002/ijc.31266.
    PubMed     Text format     Abstract available


  27. TERVASMAKI A, Mantere T, Hartikainen JM, Kauppila S, et al
    Rare missense mutations in RECQL and POLG associate with inherited predisposition to breast cancer.
    Int J Cancer. 2018 Jan 17. doi: 10.1002/ijc.31259.
    PubMed     Text format     Abstract available


  28. JOHN EM, Hines LM, Phipps AI, Koo J, et al
    Reproductive history, breast-feeding and risk of triple negative breast cancer: The Breast Cancer Etiology in Minorities (BEM) Study.
    Int J Cancer. 2018 Jan 13. doi: 10.1002/ijc.31258.
    PubMed     Text format     Abstract available


  29. MURTO MO, Artama M, Pukkala E, Visvanathan K, et al
    Breast cancer extent and survival among diabetic women in a Finnish nationwide cohort study.
    Int J Cancer. 2018 Jan 10. doi: 10.1002/ijc.31250.
    PubMed     Text format     Abstract available


  30. GE W, Clendenen TV, Afanasyeva Y, Koenig KL, et al
    Circulating Anti-Mullerian Hormone and Breast Cancer Risk: A Study in Ten Prospective Cohorts.
    Int J Cancer. 2018 Jan 8. doi: 10.1002/ijc.31249.
    PubMed     Text format     Abstract available


  31. BASU P, Ponti A, Anttila A, Ronco G, et al
    Status of implementation and organization of cancer screening in The European Union Member States-Summary results from the second European screening report.
    Int J Cancer. 2018;142:44-56.
    PubMed     Text format     Abstract available


    December 2017
  32. ANDERSON C, Engel SM, Anders CK, Nichols HB, et al
    Live birth outcomes after adolescent and young adult breast cancer.
    Int J Cancer. 2017 Dec 21. doi: 10.1002/ijc.31227.
    PubMed     Text format     Abstract available


  33. CHEN J, Yao Q, Huang M, Wang B, et al
    A Randomized Phase III Trial of Neoadjuvant Recombinant Human Endostatin, Docetaxel and Epirubicin as First-Line Therapy for Patients with Breast Cancer (CBCRT01).
    Int J Cancer. 2017 Dec 14. doi: 10.1002/ijc.31217.
    PubMed     Text format     Abstract available


  34. XIE X, Tan W, Chen B, Huang X, et al
    Preoperative prediction nomogram based on primary tumor miRNAs signature and clinical-related features for axillary lymph node metastasis in early-stage invasive breast cancer.
    Int J Cancer. 2017 Dec 11. doi: 10.1002/ijc.31208.
    PubMed     Text format     Abstract available


  35. MA L, Fu Q, Xu B, Zhou H, et al
    Breast cancer-associated mitochondrial DNA haplogroup promotes neoplastic growth via ROS-mediated AKT activation.
    Int J Cancer. 2017 Dec 11. doi: 10.1002/ijc.31207.
    PubMed     Text format     Abstract available


  36. DALLASPEZIA S, Cantamessa S, Benedetti F
    Light Therapy and Mood in Breast Cancer.
    Int J Cancer. 2017 Dec 2. doi: 10.1002/ijc.31188.
    PubMed     Text format    


  37. MCKENZIE F, Zietsman A, Galukande M, Anele A, et al
    Drivers of advanced stage at breast cancer diagnosis in the multi-country African Breast Cancer - Disparities in Outcomes (ABC-DO) study.
    Int J Cancer. 2017 Dec 2. doi: 10.1002/ijc.31187.
    PubMed     Text format     Abstract available


    November 2017
  38. LEE KR, Hwang IC, Do Han K, Jung J, et al
    Waist circumference and risk of breast cancer in Korean women: A nationwide cohort study.
    Int J Cancer. 2017 Nov 29. doi: 10.1002/ijc.31180.
    PubMed     Text format     Abstract available


  39. HIS M, Le Guelennec M, Mesrine S, Boutron-Ruault MC, et al
    Life course evolution of body size and breast cancer survival in the E3N cohort.
    Int J Cancer. 2017 Nov 27. doi: 10.1002/ijc.31177.
    PubMed     Text format     Abstract available


  40. JOHANSSON ALV, Andersson TM, Hsieh CC, Jirstrom K, et al
    Tumor characteristics and prognosis in women with pregnancy-associated breast cancer.
    Int J Cancer. 2017 Nov 23. doi: 10.1002/ijc.31174.
    PubMed     Text format     Abstract available


  41. SCHAIRER C, Pfeiffer RM, Gadalla SM
    Autoimmune diseases and breast cancer risk by tumor hormone-receptor status among elderly women.
    Int J Cancer. 2017 Nov 16. doi: 10.1002/ijc.31148.
    PubMed     Text format     Abstract available


  42. BRANDT J, Borgquist S, Almgren P, Forsti A, et al
    Thyroid associated genetic polymorphisms in relation to breast cancer risk in the Malmo Diet and Cancer Study.
    Int J Cancer. 2017 Nov 14. doi: 10.1002/ijc.31156.
    PubMed     Text format     Abstract available


  43. BARRDAHL M, Canzian F, Gaudet MM, Gapstur SM, et al
    A comprehensive analysis of polymorphic variants in steroid hormone and IGF-1 metabolism and risk of in situ breast cancer: results from the Breast and Prostate Cancer Cohort (BPC3) Consortium.
    Int J Cancer. 2017 Nov 7. doi: 10.1002/ijc.31145.
    PubMed     Text format     Abstract available


    October 2017
  44. SCHMIDT ME, Wiskemann J, Schneeweiss A, Potthoff K, et al
    Determinants of physical, affective, and cognitive fatigue: During breast cancer therapy and 12 months follow-up.
    Int J Cancer. 2017 Oct 30. doi: 10.1002/ijc.31138.
    PubMed     Text format     Abstract available


  45. HIRKO KA, Chai B, Spiegelman D, Campos H, et al
    Erythrocyte membrane fatty acids and breast cancer risk: A prospective analysis in the Nurses' Health Study II.
    Int J Cancer. 2017 Oct 26. doi: 10.1002/ijc.31133.
    PubMed     Text format     Abstract available


  46. KEINAN-BOKER L, Levine H, Leiba A, Derazne E, et al
    Adolescent obesity and adult male breast cancer in a cohort of 1,382,093 men.
    Int J Cancer. 2017 Oct 21. doi: 10.1002/ijc.31121.
    PubMed     Text format     Abstract available


  47. YU J, Wang X, Lu Q, Wang J, et al
    Extracellular 5'-nucleotidase (CD73) promotes human breast cancer cells growth through AKT/GSK-3beta/beta-catenin/cyclinD1 signaling pathway.
    Int J Cancer. 2017 Oct 19. doi: 10.1002/ijc.31112.
    PubMed     Text format     Abstract available


  48. SUROWY H, Varga D, Burwinkel B, Marme F, et al
    A low frequency haplotype spanning SLX4/FANCP constitutes a new risk locus for early-onset breast cancer (<60 years) and is associated with reduced DNA repair capacity.
    Int J Cancer. 2017 Oct 16. doi: 10.1002/ijc.31105.
    PubMed     Text format     Abstract available


  49. ZHAO B, Zhao H
    Impact of clinicopathological characteristics on the efficacy of neoadjuvant therapy in patients with human epidermal growth factor receptor-2-positive breast cancer.
    Int J Cancer. 2017 Oct 11. doi: 10.1002/ijc.31097.
    PubMed     Text format     Abstract available


  50. CONRAD C, Gotte M, Schlomann U, Roessler M, et al
    ADAM8 expression in breast cancer derived metastases: Functional implications on MMP-9 expression and transendothelial migration in breast cancer cells.
    Int J Cancer. 2017 Oct 7. doi: 10.1002/ijc.31090.
    PubMed     Text format     Abstract available


  51. NAGAPRASHANTHA LD, Adhikari R, Singhal J, Chikara S, et al
    Translational Opportunities for Broad-Spectrum Natural Phytochemicals and Targeted Agent Combinations in Breast Cancer.
    Int J Cancer. 2017 Oct 4. doi: 10.1002/ijc.31085.
    PubMed     Text format     Abstract available


    September 2017
  52. THAPA B, Bahadur Kc R, Uludag H
    Novel Targets for Sensitizing Breast Cancer Cells to TRAIL-Induced Apoptosis with siRNA Delivery.
    Int J Cancer. 2017 Sep 27. doi: 10.1002/ijc.31079.
    PubMed     Text format     Abstract available


  53. GUO S, Jing Y, Burcus NI, Lassiter BP, et al
    Nano-Pulse Stimulation Induces Potent Immune Responses, Eradicating Local Breast Cancer while Reducing Distant Metastases.
    Int J Cancer. 2017 Sep 25. doi: 10.1002/ijc.31071.
    PubMed     Text format     Abstract available


  54. WILKE CM, Hess J, Klymenko SV, Chumak VV, et al
    Expression of miRNA-26b-5p and its target TRPS1 is associated with radiation exposure in post-Chernobyl breast cancer.
    Int J Cancer. 2017 Sep 25. doi: 10.1002/ijc.31072.
    PubMed     Text format     Abstract available


  55. KIMBUNG S, Markholm I, Bjohle J, Lekberg T, et al
    Assessment of early response biomarkers in relation to long-term survival in patients with HER2-negative breast cancer receiving neoadjuvant chemotherapy plus bevacizumab: results from the phase 2 PROMIX trial.
    Int J Cancer. 2017 Sep 22. doi: 10.1002/ijc.31070.
    PubMed     Text format     Abstract available


  56. KORCH C, Hall EM, Dirks WG, Ewing M, et al
    Authentication of M14 melanoma cell line proves misidentification of MDA-MB-435 breast cancer cell line.
    Int J Cancer. 2017 Sep 22. doi: 10.1002/ijc.31067.
    PubMed     Text format     Abstract available


  57. DE GOOIJER MC, Zhang P, Weijer R, Buil LCM, et al
    The impact of P-glycoprotein and Breast Cancer Resistance Protein on the brain pharmacokinetics and pharmacodynamics of a panel of MEK inhibitors.
    Int J Cancer. 2017 Sep 16. doi: 10.1002/ijc.31052.
    PubMed     Text format     Abstract available


  58. WANG S, Huo D, Kupfer S, Alleyne D, et al
    Genetic variation in the Vitamin D related pathway and breast cancer risk in women of African ancestry in the Root Consortium.
    Int J Cancer. 2017 Sep 10. doi: 10.1002/ijc.31038.
    PubMed     Text format     Abstract available


  59. LAGENDIJK M, van Maaren MC, Saadatmand S, Strobbe LJ, et al
    Breast conserving therapy and mastectomy revisited: Breast cancer-specific survival and the influence of prognostic factors in 129,692 patients.
    Int J Cancer. 2017 Sep 7. doi: 10.1002/ijc.31034.
    PubMed     Text format     Abstract available


    August 2017
  60. BERTRAND KA, Gerlovin H, Bethea TN, Palmer JR, et al
    Pubertal growth and adult height in relation to breast cancer risk in African American women.
    Int J Cancer. 2017 Aug 28. doi: 10.1002/ijc.31019.
    PubMed     Text format     Abstract available


  61. WU AH, Vigen C, Butler LM, Tseng CC, et al
    Metabolic conditions and breast cancer risk among Los Angeles County Filipina Americans compared with Chinese and Japanese Americans.
    Int J Cancer. 2017 Aug 26. doi: 10.1002/ijc.31018.
    PubMed     Text format     Abstract available


  62. CESPEDES FELICIANO EM, Prentice RL, Aragaki AK, Neuhouser ML, et al
    Methodological Considerations for Disentangling a Risk Factor's Influence on Disease Incidence versus Post-Diagnosis Survival: The Example of Obesity and Breast and Colorectal Cancer Mortality in the Women's Health Initiative.
    Int J Cancer. 2017 Aug 18. doi: 10.1002/ijc.30931.
    PubMed     Text format     Abstract available


  63. ZHENG G, Yu H, Hemminki A, Forsti A, et al
    Familial associations of female breast cancer with other cancers.
    Int J Cancer. 2017 Aug 12. doi: 10.1002/ijc.30927.
    PubMed     Text format     Abstract available


  64. KVALE R, Myklebust TA, Engholm G, Heinavaara S, et al
    Prostate and breast cancer in four Nordic countries: A comparison of incidence and mortality trends across countries and age groups 1975-2013.
    Int J Cancer. 2017 Aug 10. doi: 10.1002/ijc.30924.
    PubMed     Text format     Abstract available


  65. WHITE AJ, Weinberg CR, Park YM, D'Aloisio AA, et al
    Sleep characteristics, light at night and breast cancer risk in a prospective cohort.
    Int J Cancer. 2017 Aug 9. doi: 10.1002/ijc.30920.
    PubMed     Text format     Abstract available


    July 2017
  66. NILENDU P, Kumar A, Kumar A, Pal JK, et al
    Breast cancer stem cells as last soldiers eluding therapeutic burn: A hard nut to crack.
    Int J Cancer. 2017 Jul 19. doi: 10.1002/ijc.30898.
    PubMed     Text format     Abstract available


  67. SANKATSING VDV, van Ravesteyn NT, Heijnsdijk EAM, de Koning HJ, et al
    Reply to Letter to Editor: 'Questionable method for estimating the influence of mammography screening on breast cancer mortality in the Netherlands.'
    Int J Cancer. 2017 Jul 6. doi: 10.1002/ijc.30873.
    PubMed     Text format    


  68. SANDSVEDEN M, Manjer J
    Selenium and breast cancer risk: A prospective nested case-control study on serum selenium levels, smoking habits and overweight.
    Int J Cancer. 2017 Jul 6. doi: 10.1002/ijc.30875.
    PubMed     Text format     Abstract available


  69. AUTIER P, Boniol M
    Questionable method for estimating the influence of mammography screening on breast cancer mortality in the Netherlands.
    Int J Cancer. 2017 Jul 6. doi: 10.1002/ijc.30874.
    PubMed     Text format    


  70. SCHIROSI L, De Summa S, Tommasi S, Paradiso A, et al
    VEGF and TWIST1 in a 16-biomarker immunoprofile useful for prognosis of breast cancer patients.
    Int J Cancer. 2017 Jul 5. doi: 10.1002/ijc.30868.
    PubMed     Text format     Abstract available


  71. BARRDAHL M, Rudolph A, Hopper JL, Southey MC, et al
    Gene-environment interactions involving functional variants: Results from the Breast Cancer Association Consortium.
    Int J Cancer. 2017 Jul 3. doi: 10.1002/ijc.30859.
    PubMed     Text format     Abstract available


    June 2017
  72. FELLER A, Schmidlin K, Bordoni A, Bouchardy C, et al
    Socioeconomic and demographic disparities in breast cancer stage at presentation and survival: A Swiss population-based study.
    Int J Cancer. 2017 Jun 28. doi: 10.1002/ijc.30856.
    PubMed     Text format     Abstract available


  73. ALMOZYAN S, Colak D, Mansour F, Alaiya A, et al
    PD-L1 promotes OCT4 and Nanog expression in breast cancer stem cells by sustaining PI3K/AKT pathway activation.
    Int J Cancer. 2017 Jun 14. doi: 10.1002/ijc.30834.
    PubMed     Text format     Abstract available


    May 2017
  74. KNIGHT JA, Fan J, Malone KE, John EM, et al
    Alcohol consumption and cigarette smoking in combination: a predictor of contralateral breast cancer risk in the WECARE Study.
    Int J Cancer. 2017 May 19. doi: 10.1002/ijc.30791.
    PubMed     Text format     Abstract available


  75. VAN DEN ENDE C, Oordt-Speets AM, Vroling H, van Agt HME, et al
    Benefits and harms of breast cancer screening with mammography in women aged 40-49 years: A systematic review.
    Int J Cancer. 2017 May 19. doi: 10.1002/ijc.30794.
    PubMed     Text format     Abstract available


  76. LOLAS HAMAMEH S, Renbaum P, Kamal L, Dweik D, et al
    Genomic analysis of inherited breast cancer among Palestinian women: Genetic heterogeneity and a founder mutation in TP53.
    Int J Cancer. 2017 May 9. doi: 10.1002/ijc.30771.
    PubMed     Text format     Abstract available


  77. BEAU AB, Lynge E, Njor SH, Vejborg I, et al
    Benefit-to-harm ratio of the Danish breast cancer screening programme.
    Int J Cancer. 2017 May 3. doi: 10.1002/ijc.30758.
    PubMed     Text format     Abstract available


    April 2017
  78. SANKATSING VDV, van Ravesteyn NT, Heijnsdijk EAM, Looman CWN, et al
    The effect of population-based mammography screening in Dutch municipalities on breast cancer mortality: 20 years of follow-up.
    Int J Cancer. 2017 Apr 29. doi: 10.1002/ijc.30754.
    PubMed     Text format     Abstract available


  79. NARKHEDE AA, Shevde LA, Rao SS
    Biomimetic strategies to recapitulate organ specific microenvironments for studying breast cancer metastasis.
    Int J Cancer. 2017 Apr 25. doi: 10.1002/ijc.30748.
    PubMed     Text format     Abstract available


    March 2017
  80. MARTINEZ VG, Crown J, Porter RK, O'Driscoll L, et al
    Neuromedin U alters bioenergetics and expands the cancer stem cell phenotype in HER2-positive breast cancer.
    Int J Cancer. 2017 Mar 24. doi: 10.1002/ijc.30705.
    PubMed     Text format     Abstract available


  81. BRINTON LA, Awuah B, Clegg-Lamptey JN, Wiafe-Addai B, et al
    Design considerations for identifying breast cancer risk factors in a population-based study in Africa.
    Int J Cancer. 2017 Mar 13. doi: 10.1002/ijc.30688.
    PubMed     Text format     Abstract available


  82. PARK YM, White AJ, Nichols HB, O'Brien KM, et al
    The association between metabolic health, obesity phenotype and the risk of breast cancer.
    Int J Cancer. 2017 Mar 7. doi: 10.1002/ijc.30684.
    PubMed     Text format     Abstract available


  83. GADEYNE S, Menvielle G, Kulhanova I, Bopp M, et al
    The turn of the gradient? Educational differences in breast cancer mortality in 18 European populations during the 2000s.
    Int J Cancer. 2017 Mar 7. doi: 10.1002/ijc.30685.
    PubMed     Text format     Abstract available


  84. WANG J, Shidfar A, Ivancic D, Ranjan M, et al
    Overexpression of lipid metabolism genes and PBX1 in the contralateral breasts of women with estrogen receptor-negative breast cancer.
    Int J Cancer. 2017 Mar 6. doi: 10.1002/ijc.30680.
    PubMed     Text format     Abstract available


  85. VAN DEN BRANDT PA, Schulpen M
    Mediterranean diet adherence and risk of postmenopausal breast cancer: results of a cohort study and meta-analysis.
    Int J Cancer. 2017 Mar 5. doi: 10.1002/ijc.30654.
    PubMed     Text format     Abstract available


    February 2017
  86. STROTBEK M, Schmid S, Sanchez-Gonzalez I, Boerries M, et al
    miR-181 elevates Akt signaling by co-targeting PHLPP2 and INPP4B phosphatases in luminal breast cancer.
    Int J Cancer. 2017 Feb 22. doi: 10.1002/ijc.30661.
    PubMed     Text format     Abstract available


  87. LIN X, Chen W, Wei F, Zhou BP, et al
    POMC maintains tumor-initiating properties of tumor tissue-derived long-term-cultured breast cancer stem cells.
    Int J Cancer. 2017 Feb 18. doi: 10.1002/ijc.30658.
    PubMed     Text format     Abstract available


    January 2017
  88. ROSNER B, Eliassen AH, Toriola AT, Chen WY, et al
    Weight and weight changes in early adulthood and later breast cancer risk.
    Int J Cancer. 2017 Jan 30. doi: 10.1002/ijc.30627.
    PubMed     Text format     Abstract available


  89. HALPERN N, Sonnenblick A, Uziely B, Divinsky L, et al
    Oncotype Dx recurrence score among BRCA1/2 germline mutation carriers with hormone receptors positive breast cancer.
    Int J Cancer. 2017 Jan 24. doi: 10.1002/ijc.30616.
    PubMed     Text format     Abstract available


    December 2016
  90. BENNETT L, Quinn J, McCall P, Mallon EA, et al
    High IKKalpha expression is associated with reduced time to recurrence and cancer specific survival in oestrogen receptor (ER)-positive breast cancer.
    Int J Cancer. 2016 Dec 22. doi: 10.1002/ijc.30578.
    PubMed     Text format     Abstract available


  91. XU W, Jia G, Cai N, Huang S, et al
    A 16 Yin Yang Gene Expression Ratio Signature for ER+/Node- Breast Cancer.
    Int J Cancer. 2016 Dec 7. doi: 10.1002/ijc.30556.
    PubMed     Text format     Abstract available


  92. CHEN S, Wang RX, Liu Y, Yang WT, et al
    PD-L1 expression of the residual tumor serves as a prognostic marker in local advanced breast cancer after neoadjuvant chemotherapy.
    Int J Cancer. 2016 Dec 7. doi: 10.1002/ijc.30552.
    PubMed     Text format     Abstract available


  93. MATEJCIC M, de Batlle J, Ricci C, Biessy C, et al
    Biomarkers of folate and vitamin B12 and breast cancer risk: Report from the EPIC cohort.
    Int J Cancer. 2016 Dec 1. doi: 10.1002/ijc.30536.
    PubMed     Text format     Abstract available


    November 2016
  94. KARASNEH RA, Murray LJ, Cardwell CR
    Cardiac glycosides and breast cancer risk: A systematic review and meta-analysis of observational studies.
    Int J Cancer. 2016 Nov 15. doi: 10.1002/ijc.30520.
    PubMed     Text format     Abstract available


  95. VAN LUIJT PA, Heijnsdijk EA, de Koning HJ
    Cost-effectiveness of the Norwegian breast cancer screening program.
    Int J Cancer. 2016 Nov 11. doi: 10.1002/ijc.30513.
    PubMed     Text format     Abstract available


  96. YANG H, Brand JS, Fang F, Chiesa F, et al
    Time-dependent risk of depression, anxiety and stress-related disorders in patients with invasive and in-situ breast cancer.
    Int J Cancer. 2016 Nov 11. doi: 10.1002/ijc.30514.
    PubMed     Text format     Abstract available


  97. BODELON C, Oh H, Chatterjee N, Garcia-Closas M, et al
    Association between breast cancer genetic susceptibility variants and terminal duct lobular unit involution of the breast.
    Int J Cancer. 2016 Nov 9. doi: 10.1002/ijc.30512.
    PubMed     Text format     Abstract available


  98. BHUSARI P, Vatsa R, Singh G, Parmar M, et al
    Development of Lu-177-trastuzumab for radioimmunotherapy of HER2 expressing breast cancer and its feasibility assessment in breast cancer patients.
    Int J Cancer. 2016 Nov 3. doi: 10.1002/ijc.30500.
    PubMed     Text format     Abstract available


    October 2016
  99. FERRONI P, Santilli F, Cavaliere F, Simeone P, et al
    Oxidant stress as a major determinant of platelet activation in invasive breast cancer.
    Int J Cancer. 2016 Oct 26. doi: 10.1002/ijc.30488.
    PubMed     Text format     Abstract available


    September 2016
  100. SIMONSSON M, Bjorner S, Markkula A, Nodin B, et al
    The prognostic impact of COX-2 expression in breast cancer depends on oral contraceptive history, preoperative NSAID use, and tumor size.
    Int J Cancer. 2016 Sep 15. doi: 10.1002/ijc.30432.
    PubMed     Text format     Abstract available


  101. VAN DER WAAL D, Ripping TM, Verbeek AL, Broeders MJ, et al
    Breast cancer screening effect across breast density strata: A case-control study.
    Int J Cancer. 2016 Sep 15. doi: 10.1002/ijc.30430.
    PubMed     Text format     Abstract available


  102. STRAND F, Humphreys K, Eriksson M, Li J, et al
    Longitudinal fluctuation in mammographic percent density differentiates between interval and screen-detected breast cancer.
    Int J Cancer. 2016 Sep 12. doi: 10.1002/ijc.30427.
    PubMed     Text format     Abstract available


  103. SYNNOTT NC, Murray A, McGowan PM, Kiely M, et al
    Mutant p53: A Novel Target for the Treatment of Patients with Triple-Negative Breast Cancer?
    Int J Cancer. 2016 Sep 12. doi: 10.1002/ijc.30425.
    PubMed     Text format     Abstract available


  104. ROMIEU I, Ferrari P, Chajes V, de Batlle J, et al
    Fiber intake modulates the association of alcohol intake with breast cancer.
    Int J Cancer. 2016 Sep 6. doi: 10.1002/ijc.30415.
    PubMed     Text format     Abstract available


  105. HE W, Lindstrom LS, Hall P, Czene K, et al
    Cause-specific mortality in women with breast cancer in situ.
    Int J Cancer. 2016 Sep 4. doi: 10.1002/ijc.30413.
    PubMed     Text format     Abstract available


    August 2016
  106. NOMURA SJ, Dash C, Rosenberg L, Yu J, et al
    Adherence to diet, physical activity and body weight recommendations and breast cancer incidence in the Black Women's Health Study.
    Int J Cancer. 2016 Aug 31. doi: 10.1002/ijc.30410.
    PubMed     Text format     Abstract available


  107. FRY EA, Taneja P, Inoue K
    Oncogenic and tumor-suppressive mouse models for breast cancer engaging HER2/neu.
    Int J Cancer. 2016 Aug 23. doi: 10.1002/ijc.30399.
    PubMed     Text format     Abstract available


  108. KIISKI JI, Fagerholm R, Tervasmaki A, Pelttari LM, et al
    FANCM c.5101C>T mutation associates with breast cancer survival and treatment outcome.
    Int J Cancer. 2016 Aug 20. doi: 10.1002/ijc.30394.
    PubMed     Text format     Abstract available


  109. KIM HJ, Min A, Im SA, Jang H, et al
    Anti-tumor Activity of the ATR Inhibitor AZD6738 in HER2 positive Breast Cancer Cells.
    Int J Cancer. 2016 Aug 8. doi: 10.1002/ijc.30373.
    PubMed     Text format     Abstract available


  110. LI J, Humphreys K, Eriksson M, Dar H, et al
    Worse quality of life in young and recently-diagnosed breast cancer survivors compared to female survivors of other cancers: A cross-sectional study.
    Int J Cancer. 2016 Aug 3. doi: 10.1002/ijc.30370.
    PubMed     Text format     Abstract available


    July 2016
  111. DARLIX A, Lamy PJ, Lopez-Crapez E, Braccini AL, et al
    Serum NSE, MMP-9 and HER2 extra-cellular domain are associated with brain metastases in metastatic breast cancer patients: Predictive biomarkers for brain metastases?
    Int J Cancer. 2016 Jul 27. doi: 10.1002/ijc.30290.
    PubMed     Text format     Abstract available


  112. CADEAU C, Fournier A, Mesrine S, Clavel-Chapelon F, et al
    Postmenopausal breast cancer risk and interactions between body mass index, menopausal hormone therapy use, and vitamin D supplementation: Evidence from the E3N cohort.
    Int J Cancer. 2016 Jul 23. doi: 10.1002/ijc.30282.
    PubMed     Text format     Abstract available


  113. KIM SB, Wildiers H, Krop IE, Smitt M, et al
    Relationship between tumor biomarkers and efficacy in TH3RESA, a phase III study of trastuzumab emtansine (T-DM1) versus treatment of physician's choice in previously treated HER2-positive advanced breast cancer.
    Int J Cancer. 2016 Jul 18. doi: 10.1002/ijc.30276.
    PubMed     Text format     Abstract available


  114. AYRAULT-PIAULT S, Grosclaude P, Daubisse-Marliac L, Pascal J, et al
    Are disparities of waiting times for breast cancer care related to socio-economic factors? A regional population-based study (France).
    Int J Cancer. 2016 Jul 12. doi: 10.1002/ijc.30266.
    PubMed     Text format     Abstract available


  115. INOUE K, Fry EA
    Aberrant splicing of the DMP1-ARF-MDM2-p53 pathway in cancer.
    Int J Cancer. 2016;139:33-41.
    PubMed     Text format     Abstract available


    June 2016
  116. ABREU MH, Abreu PH, Afonso N, Pereira D, et al
    Patterns of recurrence and treatment in male breast cancer: A clue to prognosis?
    Int J Cancer. 2016 Jun 9. doi: 10.1002/ijc.30225.
    PubMed     Text format     Abstract available


    May 2016
  117. MANTHRAVADI S, Shrestha A, Madhusudhana S
    Impact of statin use on cancer recurrence and mortality in breast cancer: A systematic review and meta-analysis.
    Int J Cancer. 2016 May 13. doi: 10.1002/ijc.30185.
    PubMed     Text format     Abstract available


  118. JOYCE DP, Kerin MJ, Dwyer RM
    Exosome-encapsulated microRNAs as circulating biomarkers for breast cancer.
    Int J Cancer. 2016 May 11. doi: 10.1002/ijc.30179.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Breast Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: